We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$782M
AUM Growth
+$134M
Cap. Flow
-$119M
Cap. Flow %
-15.2%
Top 10 Hldgs %
66.62%
Holding
166
New
28
Increased
41
Reduced
46
Closed
40

Top Buys

Rank Stock Value
1
ORMP icon
Oramed Pharmaceuticals
ORMP
+$4.16M
2
NKTR icon
Nektar Therapeutics
NKTR
+$3.04M
3
VKTX icon
Viking Therapeutics
VKTX
+$1.95M
4
FOLD
Amicus Therapeutics
FOLD
+$1.63M
5
GNPX icon
Genprex
GNPX
+$1.42M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$40.1M
2
NVO
Novo Nordisk
NVO
+$19.8M
3
SSKN
Strata Skin Sciences
SSKN
+$3.45M
4
INCY icon
Incyte
INCY
+$2.77M
5
AZN icon
AstraZeneca
AZN
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 15.01%
2 Consumer Staples 0.29%
3 Financials 0.12%
4 Technology 0.09%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
26
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$5.18M 0.66%
540
+40
+8% +$3.77K
GBT
27
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.99M 0.64%
1,312
+476
+57% +$21.1K
ESPR
28
DELISTED
Esperion Therapeutics
ESPR
$4.45M 0.57%
100,369
-48,335
-33% -$2.22M
AVEO
29
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.03M 0.52%
1,218
-3
-0.2% -$77
ORMP icon
30
Oramed Pharmaceuticals
ORMP
$171M
$3.88M 0.5%
+801,242
New +$4.16M
ISEE
31
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.82M 0.49%
1,618,820
+308,742
+24% +$770K
NKTR icon
32
CALL
Nektar Therapeutics
NKTR
$2.39B
$3.61M 0.46%
39
-5
-11% -$4.27K
BCLI
33
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$3.46M 0.44%
60,464
-1,518
-2% -$91.8K
NTBL
34
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$3.45M 0.44%
60,735
+7,702
+15% +$488K
OTLK icon
35
Outlook Therapeutics
OTLK
$169M
$3.32M 0.42%
20,968
-2,112
-9% -$297K
MDGL icon
36
CALL
Madrigal Pharmaceuticals
MDGL
$12.4B
$3.3M 0.42%
154
+74
+93% +$18.6K
VKTX icon
37
Viking Therapeutics
VKTX
$3.93B
$2.85M 0.36%
+163,463
New +$1.95M
FOLD
38
CALL
DELISTED
Amicus Therapeutics
FOLD
$2.84M 0.36%
2,350
+1,904
+427% +$26.6K
SGMO
39
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.66M 0.34%
156,913
-11,326
-7% -$172K
ALKS icon
40
CALL
Alkermes
ALKS
$8.47B
$2.42M 0.31%
+571
New +$24.8K
FOLD
41
PUT
DELISTED
Amicus Therapeutics
FOLD
$2M 0.26%
1,656
+220
+15% +$3.08K
FOLD
42
DELISTED
Amicus Therapeutics
FOLD
$1.87M 0.24%
155,044
+116,700
+304% +$1.63M
GNPX icon
43
Genprex
GNPX
$4.05M
$1.66M 0.21%
17
+8
+89% +$1.42M
SLNO
44
DELISTED
Soleno Therapeutics
SLNO
$1.63M 0.21%
50,354
-2,043
-4% -$74.2K
MRNS
45
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.59M 0.2%
399
+82
+26% +$2.33K
RKDA icon
46
Arcadia Biosciences
RKDA
$1.37M
$1.35M 0.17%
6,936
+3,891
+128% +$978K
ADVM
47
CALL
DELISTED
Adverum Biotechnologies
ADVM
$1.35M 0.17%
223
-148
-40% -$8.31K
CYTR
48
DELISTED
CytRx Corp
CYTR
$1.33M 0.17%
1,269,731
-404,700
-24% -$457K
MNKD icon
49
PUT
MannKind Corp
MNKD
$1.21B
$1.31M 0.17%
7,154
+2,604
+57% +$3.99K
APTX
50
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.19M 0.15%
41,037
-820
-2% -$19.9K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sabby Management held 166 positions worth $782M, up 21% from $647M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $119M in Q3 2018, closing 40 positions and reducing 46 holdings. Its most notable exit was Novo Nordisk, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 26% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Sabby Management opened a new position in Oramed Pharmaceuticals worth $3.88M.

  • Sabby Management's largest Q3 2018 buy was Oramed Pharmaceuticals: 801,242 shares worth $3.88M.
  • Sabby Management added most to Nektar Therapeutics in Q3 2018, an estimated $3.04M increase.
  • Sabby Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $40.1M.
  • Sabby Management fully exited Novo Nordisk in Q3 2018, selling an estimated $19.8M.
  • Sabby Management's ten largest holdings make up 67% of its $782M portfolio in Q3 2018.
  • Sabby Management opened 28 new positions and closed 40 in Q3 2018.
  • Sabby Management's portfolio value rose 21% quarter-over-quarter to $782M.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.